Patterns of care and burden of chronic idiopathic thrombocytopenic purpura in Brazil

References

• George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-207
   PubMed Web of Science ®Google Scholar
• British Society for Haematology, BSH. Guidelines fo the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Hematol 2003;120:574-596
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93
   PubMed Web of Science ®Google Scholar
• Fogarty PF. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematol Oncol Clin North Am 2009;23:1213-21
   PubMed Web of Science ®Google Scholar
• Daou S, Federici L, Zimmer J, et al. Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. Eur J Intern Med 2008;19:447-51
   PubMed Web of Science ®Google Scholar
• Cooper N, Terrinoni I, Newland A. The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia. Ther Adv Hematol 2012;3:291-8
   PubMedGoogle Scholar
• Despotovic JM, Neunert CE. Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia? Hematology Am Soc Hematol Educ Program 2013;2013:283-5
   PubMedGoogle Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86
   PubMed Web of Science ®Google Scholar
• George JN. Sequence of treatments for adults with primary immune thrombocytopenia. Am J Hematol 2012;87(Suppl1):S12-S15
   Web of Science ®Google Scholar
• Ministério da Saúde. Púrpura Trombocitopênica Idiopática. Portaria SAS/MS n° 1.316, de 22 de novembro de 2013. In: Ministério da Saúde, editor. Protocolo Clínico e Diretrizes Terapêuticas. Ministério da Saúde. Brasília; 2013
   Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-207
   PubMed Web of Science ®Google Scholar
• Associação Médica Brasileira. Classificação Brasileira Hierarquizada de Procedimentos Médicos. Associação Médica Brasileira. São Paulo; 2014
   Google Scholar
• DATASUS. Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS. Ministério da Saúde. Brasília; 2016
   Google Scholar
• Agência Nacional de Vigilância Sanitária. Preços Máximos de Medicamentos por Princípio Ativo. Agência Nacional de Vigilância Sanitária. Brasília; 2015
   Google Scholar
• Ministério da Saúde. Banco de Preços em Saúde. Ministério da Saúde. Brasília; 2015
   Google Scholar
• Stephens JM, Handke B, Doshi JA. International survey of methods used in health technology assessment (HTA): does practice meet the principles proposed for good research? Compar Effect Res 2012;2:29-44
   Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889-99
   PubMed Web of Science ®Google Scholar
• Bauer M, Baumann A, Berger K, et al. A retrospective observational single-centre study on the burden of immune thrombocytopenia (ITP). Onkologie 2012;35:342-8
   PubMedGoogle Scholar
• NICE. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. NICE. London; 2010
   Google Scholar
• Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623-34
   PubMed Web of Science ®Google Scholar
• NICE. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. NICE. London; 2011
   Google Scholar
• Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69
   PubMed Web of Science ®Google Scholar
• Moulis G, Lapeyre-Mestre M, Montastruc JL, et al. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Autoimmun Rev 2015;14:168-73
   PubMed Web of Science ®Google Scholar
• Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966-74
   PubMed Web of Science ®Google Scholar
• Khellaf M, Le Moine JG, Poitrinal P, et al. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol 2011;90:441-6
   PubMed Web of Science ®Google Scholar
• Kaya E, Erkurt MA, Aydogdu I, et al. Retrospective analysis of patients with idiopathic thrombocytopenic purpura from Eastern Anatolia. Med Princ Pract 2007;16:100-6
   PubMed Web of Science ®Google Scholar
• Pamuk GE, Pamuk ON, Baslar Z, et al. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 2002;81:436-40
   PubMed Web of Science ®Google Scholar
• Sailer T, Lechner K, Panzer S, et al. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006;91:1041-5
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991;77:31-3
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436-42
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-54
   PubMed Web of Science ®Google Scholar
• Schiavotto C, Rodeghiero F. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases. Haematologica 1993;78:22-8
   PubMedGoogle Scholar
• Deuson R, Danese M, Mathias SD, et al. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. J Med Econ 2012;15:956-76
   PubMedGoogle Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393-402
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-8
   PubMed Web of Science ®Google Scholar